Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 122

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1
Chunk 122
---
 
     (625) 
    $-  
     -  
    $- 
  
    Outstanding as of December 31, 2024 
     2,887,822  
    $8.06  
     7.6  
    $- 
  
    Exercisable as of December 31, 2024 
     1,854,764  
    $11.54  
     6.8  
    $- 
  
    Vested and expected to vest as of December 31, 2024 
     2,887,822  
    $8.06  
     7.6  
    $- 

The
following table summarizes the total stock-based compensation expense included in the consolidated statements of operations for the periods
presented:

 SCHEDULE
OF STOCK BASED COMPENSATION EXPENSES 

    2024  
    2023 

    For the year ended December 31, 

    2024  
    2023 
  
    Research and development 
    $624,480  
    $792,273 
  
    General and administrative 
     1,681,369  
     2,173,665 
  
    Total stock-based compensation expense 
    $2,305,849  
    $2,965,938 

As
of December 31, 2024, total compensation cost not yet recognized related to unvested stock options was approximately $1.0 million, which
is expected to be recognized over a weighted-average period of approximately 1.5 years.

The
Company estimates the fair value of stock options on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes
option-pricing model requires estimates of highly subjective assumptions, which affect the fair value of each stock option. The weighted
average inputs used to measure the value of the options granted during the years ended December 31, 2024 and 2023 are presented in the
table below. The weighted average fair value of stock options issued during the years ended December 31, 2024 and 2023 was $1.31 and
$1.43 per share, respectively.

 SCHEDULE
OF WEIGHTED AVERAGE INPUTS USED TO MEASURE VALUE OF OPTIONS GRANTED 

    2024  
    2023 
  
    Exercise price